98%
921
2 minutes
20
Background: Systemic inflammation in rheumatoid arthritis (RA) is associated with metabolic changes. We used nuclear magnetic resonance (NMR) spectroscopy-based metabolomics to assess the relationship between an objective measure of systemic inflammation [C-reactive protein (CRP)] and both the serum and urinary metabolome in patients with newly presenting RA.
Methods: Serum (n=126) and urine (n=83) samples were collected at initial presentation from disease modifying anti-rheumatic drug naïve RA patients for metabolomic profile assessment using 1-dimensional H-NMR spectroscopy. Metabolomics data were analysed using partial least square regression (PLS-R) and orthogonal projections to latent structure discriminant analysis (OPLS-DA) with cross validation.
Results: Using PLS-R analysis, a relationship between the level of inflammation, as assessed by CRP, and the serum (p=0.001) and urinary (p<0.001) metabolome was detectable. Likewise, following categorisation of CRP into tertiles, patients in the lowest CRP tertile and the highest CRP tertile were statistically discriminated using OPLS-DA analysis of both serum (p=0.033) and urinary (p<0.001) metabolome. The most highly weighted metabolites for these models included glucose, amino acids, lactate, and citrate. These findings suggest increased glycolysis, perturbation in the citrate cycle, oxidative stress, protein catabolism and increased urea cycle activity are key characteristics of newly presenting RA patients with elevated CRP.
Conclusions: This study consolidates our understanding of a previously identified relationship between serum metabolite profile and inflammation and provides novel evidence that there is a relationship between urinary metabolite profile and inflammation as measured by CRP. Identification of these metabolic perturbations provides insights into the pathogenesis of RA and may help in the identification of therapeutic targets.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507469 | PMC |
http://dx.doi.org/10.3389/fimmu.2021.676105 | DOI Listing |
JMIR Res Protoc
September 2025
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Background: Various media are used to enhance public understanding about diseases. While mobile health apps are widely used, there is little proof for using such apps to raise awareness of skin diseases.
Objective: We intend to develop an app, called DEDIKASI-app, to raise awareness of skin diseases, including leprosy.
Vestn Oftalmol
September 2025
Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia.
Unlabelled: Retinoblastoma is a malignant retinal tumor characterized by an aggressive clinical course, with frequent recurrences and the emergence of new foci even during chemotherapy.
Objective: This study investigated the subpopulation composition of peripheral blood lymphocytes in children with newly diagnosed untreated retinoblastoma.
Material And Methods: A total of 24 children (48 eyes) were examined between December 20, 2023, and September 1, 2024; retinoblastoma was diagnosed in 28 eyes.
Eur J Neurol
September 2025
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background: Frontotemporal dementia (FTD) encompasses diverse clinical phenotypes, primarily characterized by behavioral and/or language dysfunction. A newly characterized variant, semantic behavioral variant FTD (sbvFTD), exhibits predominant right temporal atrophy with features bridging behavioral variant FTD (bvFTD) and semantic variant primary progressive aphasia (svPPA). This study investigates the longitudinal structural MRI correlates of these FTD variants, focusing on cortical and subcortical structural damage to aid differential diagnosis and prognosis.
View Article and Find Full Text PDFJ Am Coll Surg
September 2025
Division of Research and Optimal Patient Care, American College of Surgeons, Chicago, IL.
Background: The NSQIP Pediatric Semi-annual report (NSQIP Ped SAR) provides hospitals with risk-adjusted benchmarked results for comparative performance based on 1 year of data. These data are 6 to 18 months old due to requirements for data processing and modeling and this delay potentially limits its usefulness for hospital surgical quality improvement efforts. A timelier reporting mechanism is needed.
View Article and Find Full Text PDFPalliat Med Rep
May 2025
Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Background: Although early palliative care (EPC) integrated into standard cancer care improves the quality of lives of patients with cancer and their caregivers, implementation strategies for EPC programs in individual clinical settings have not been established.
Objective: This pilot randomized controlled trial explored the feasibility, acceptability, and effectiveness of nurse-led EPC using a screening-based program that focused on the individual concerns of patients with advanced lung cancer and their caregivers.
Design: This pilot study was a parallel-group randomized controlled trial in which patients were randomly assigned (1:1) to receive either EPC using the care program or standard care alone.